Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early technology assessment of using whole genome sequencing in personalized oncology.
Simons M, Van De Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, Van Harten W, Retèl V. Simons M, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):343-351. doi: 10.1080/14737167.2021.1917386. Epub 2021 Jun 1. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33910430 Review.
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Simons MJHG, Retèl VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, Aerts JGJV, Mfumbilwa ZA, Roepman P, Coupé VMH, Uyl-de Groot CA, van Harten WH, Joore MA. Simons MJHG, et al. Pharmacoeconomics. 2021 Dec;39(12):1429-1442. doi: 10.1007/s40273-021-01073-y. Epub 2021 Aug 18. Pharmacoeconomics. 2021. PMID: 34405371 Free PMC article.
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA, Simons MJHG, Ramaekers B, Retèl VP, Mankor JM, Groen HJM, Aerts JGJV, Joore M, Wilschut JA, Coupé VMH. Mfumbilwa ZA, et al. Among authors: simons mjhg. Pharmacoeconomics. 2024 Apr;42(4):419-434. doi: 10.1007/s40273-023-01344-w. Epub 2024 Jan 9. Pharmacoeconomics. 2024. PMID: 38194023 Free PMC article.
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients.
Wang X, Yamato K, Kojima Y, Paris JJ, Peterse EFP, Simons MJHG, Bennison C. Wang X, et al. Among authors: simons mjhg. Pharmacoeconomics. 2023 Oct;41(10):1263-1274. doi: 10.1007/s40273-023-01288-1. Epub 2023 Jun 15. Pharmacoeconomics. 2023. PMID: 37318748 Free PMC article.
12 results